Inflammation and Fibrosis

Employ EpiAirway’s diverse inventory of healthy and diseased donors (Asthma, COPD, Smokers) to elucidate molecular pathways involved in respiratory diseases and assess therapeutic efficacy of inhaled or systemic drugs.

METHODS

EpiAirway tissues (Figure 1) are equilibrated overnight under standard culture conditions (37°C, 5% CO2) with EpiAirway Assay Media (AIR-100-ASY).  18-24 hours later the apical surface of the tissue is washed twice by adding 400 μl DPBS into the culture insert and carefully aspirating to remove all liquid.  Culture supernatants are aspirated and replaced with fresh, pre-warmed media.  EpiAirway is exposed to test material.  Following exposure, test material is rinsed from the tissue with PBS and tissues are harvested for the evaluation of inflammatory/fibrotic biomarkers.

RESULTS

EpiAirway and EpiAirwayFT are used to model and study inflammatory diseases such as Asthma, COPD and fibrosis.   Intrinsic inflammatory responses are observed between healthy and diseased donors.  Furthermore, induction by exogenous stimuli including virus, proinflammatory cytokines and pro-fibrotic agents exacerbate inflammatory responses, tissue remodeling and cilia function.

CONCLUSIONS

EpiAirway models have been successfully utilized to study airway inflammation, goblet cell hyperplasia, cilia function/mucociliary clearance and fibrosis.

 

For more information, view Technical References.
Learn more about EpiAirway.

Share on FacebookTweet about this on TwitterShare on LinkedInEmail this to someone